Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.